SWARM_Systemic release of growth factors after radioembolization of hepatic malignancies

SWARM_Systemic release of growth factors after radioembolization of hepatic malignancies - SWARM

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009916

Enrollment

500

Registered

2022-03-28

Start date

2022-04-08

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C78.5 C78.4 C22.0 C50.9 C78.7

Interventions

Group 1: The radioembolization in hepatic malignancies is a routine clinical procedure. Serum samples for growth factor determination from peripheral venous blood are taken at three points in time - b

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: hepatic primary and secondary tumors Indication for radioembolization Chemotherapy paused at least 2 weeks before inclusion Cortisone therapy has been paused at least 2 weeks before inclusion

Exclusion criteria

Exclusion criteria: Life expectancy 70% chronic infections severe ascites Contraindications for angiography, MRI contrast agent (Gd-EOB-DTPA), Autoimmune diseases or inflammatory bowel diseases

Design outcomes

Primary

Measure	Time frame
Evaluation of growth hormone release as a prognostic marker for overall survival after local ablative radioembolization therapy (SIRT) of hepatic malignancies.	—

Secondary

Measure	Time frame
Correlation between baseline interleukin 6 levels and liver toxicity during follow-up and survival	—

Countries

Germany

Contacts

Public ContactChristel Besseler

Klinik und Poliklinik für Radiologie Klinikum der Universität München Campus Großhadern

christel.besseler@med.uni-muenchen.de(089) 4400-73647

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026